$NEOT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Evofem Biosciences, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Evofem Biosciences, Inc.. Get notifications about new insider transactions in Evofem Biosciences, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 13 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 1.98 | 3,715 | 7,356 | 12,541 | 8.8 K to 12.5 K (+42.09 %) |
Aug 13 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Buy | P | 2.11 | 10,000 | 21,100 | 341,813 | 331.8 K to 341.8 K (+3.01 %) |
Jul 27 2018 | NEOT | Evofem Biosciences ... | O'Brien Anthony Stephen | Director | Option Exercise | A | 2.31 | 12,875 | 29,741 | 12,875 | |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 2.46 | 2,840 | 6,986 | 8,826 | 11.7 K to 8.8 K (-24.34 %) |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 11,666 | 0 | 11,666 | 0 to 11.7 K |
Jul 03 2018 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 2.46 | 119,510 | 293,995 | 180,490 | 300 K to 180.5 K (-39.84 %) |
Jul 03 2018 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Grant | A | 0.00 | 300,000 | 0 | 300,000 | 0 to 300 K |
Jul 03 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 2.46 | 493,187 | 1,213,240 | 331,813 | 825 K to 331.8 K (-59.78 %) |
Jul 03 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Grant | A | 0.00 | 825,000 | 0 | 825,000 | 0 to 825 K |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Grant | A | 0.00 | 70,000 | 0 | 70,000 | 0 to 70 K |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | M | 0.00 | 75,000 | 0 | 0 | |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | M | 0.00 | 75,000 | 0 | 75,000 | 0 to 75 K |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 2.46 | 4,748 | 11,680 | 8,985 | 13.7 K to 9 K (-34.57 %) |
Jul 03 2018 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Grant | A | 0.00 | 13,733 | 0 | 13,733 | 0 to 13.7 K |
May 24 2018 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Option Exercise | P | 7.50 | 2,127,659 | 15,957,443 | 2,127,659 | |
May 24 2018 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Buy | P | 4.69 | 2,127,659 | 9,978,721 | 9,165,157 | 7 M to 9.2 M (+30.23 %) |
May 10 2018 | NEOT | Evofem Biosciences ... | Kamdar Kim P. | Director | Option Exercise | A | 6.99 | 12,875 | 89,996 | 12,875 | |
May 09 2018 | NEOT | Evofem Biosciences ... | Greer Gillian | Director | Option Exercise | A | 6.99 | 12,875 | 89,996 | 12,875 | |
May 09 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 6.99 | 12,875 | 89,996 | 12,875 | |
May 09 2018 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 6.99 | 12,875 | 89,996 | 12,875 | |
May 09 2018 | NEOT | Evofem Biosciences ... | Hall William Walmsley | Director | Option Exercise | A | 6.99 | 12,875 | 89,996 | 12,875 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | O'Brien Anthony Stephen | Director | Option Exercise | A | 7.29 | 24,691 | 179,997 | 24,691 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 7.29 | 24,691 | 179,997 | 24,691 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 7.29 | 15,000 | 109,350 | 15,000 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 7.29 | 825,000 | 6,014,250 | 825,000 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 7.29 | 225,000 | 1,640,250 | 225,000 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 7.29 | 24,691 | 179,997 | 24,691 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Hall William Walmsley | Director | Option Exercise | A | 7.29 | 24,691 | 179,997 | 24,691 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Greer Gillian | Director | Option Exercise | A | 7.29 | 24,691 | 179,997 | 24,691 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Option Exercise | A | 7.29 | 275,000 | 2,004,750 | 275,000 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Option Exercise | A | 7.29 | 300,000 | 2,187,000 | 300,000 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Option Exercise | A | 7.29 | 260,000 | 1,895,400 | 260,000 | |
Mar 14 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 7.29 | 260,000 | 1,895,400 | 260,000 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 43.64 | 770 | 33,603 | 770 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 79.87 | 6,719 | 536,647 | 6,719 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 46.36 | 9,994 | 463,322 | 9,994 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 46.36 | 12,833 | 594,938 | 12,833 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 46.36 | 19,249 | 892,384 | 19,249 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 46.36 | 3,850 | 178,486 | 3,850 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Option Exercise | A | 46.36 | 10,266 | 475,932 | 10,266 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Option Exercise | A | 46.36 | 12,833 | 594,938 | 12,833 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Option Exercise | A | 46.36 | 7,699 | 356,926 | 7,699 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 46.36 | 1,283 | 59,480 | 1,283 | |
Jan 18 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 46.36 | 3,850 | 178,486 | 3,850 | |
Jun 23 2017 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Option Exercise | A | 2.27 | 65,000 | 147,550 | 65,000 | |
Jun 23 2017 | NEOT | Neothetics, Inc. | Feldman Maria | VP, Clinical Resear ... | Option Exercise | A | 2.27 | 140,000 | 317,800 | 140,000 | |
Jun 22 2017 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 2.19 | 12,450 | 27,266 | 12,450 | |
Jun 21 2017 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 2.19 | 12,450 | 27,266 | 12,450 | |
Jun 21 2017 | NEOT | Neothetics, Inc. | Nugent Jeffrey M | Director | Option Exercise | A | 2.19 | 12,450 | 27,266 | 12,450 | |
Jun 21 2017 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Option Exercise | A | 2.19 | 12,450 | 27,266 | 12,450 | |
May 15 2017 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 2.15 | 63,500 | 136,525 | 63,500 | |
May 11 2017 | NEOT | Neothetics, Inc. | Nugent Jeffrey M | Director | Option Exercise | A | 2.15 | 63,500 | 136,525 | 63,500 | |
May 11 2017 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 2.15 | 63,500 | 136,525 | 63,500 | |
Mar 06 2017 | NEOT | Neothetics, Inc. | Feldman Maria | VP Clinical Researc ... | Option Exercise | A | 1.43 | 90,000 | 128,700 | 90,000 | |
Mar 06 2017 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Option Exercise | A | 1.43 | 100,000 | 143,000 | 100,000 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Option Exercise | A | 1.13 | 12,450 | 14,069 | 12,450 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | Nugent Jeffrey M | Director | Option Exercise | A | 1.13 | 24,590 | 27,787 | 24,590 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | Nugent Jeffrey M | Director | Option Exercise | A | 1.13 | 12,450 | 14,069 | 12,450 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 1.13 | 24,590 | 27,787 | 24,590 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | M | 1.13 | 16,393 | 18,524 | 0 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 1.13 | 16,393 | 18,524 | 16,393 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 1.13 | 12,450 | 14,069 | 12,450 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Buy | M | 1.13 | 16,393 | 18,524 | 16,393 | 0 to 16.4 K |
Jun 23 2016 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 1.13 | 24,590 | 27,787 | 24,590 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 1.13 | 16,393 | 18,524 | 16,393 | |
Jun 23 2016 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 1.13 | 12,450 | 14,069 | 12,450 | |
Feb 08 2016 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Option Exercise | A | 0.97 | 35,000 | 33,954 | 35,000 | |
Feb 08 2016 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Option Exercise | A | 0.97 | 45,000 | 43,655 | 45,000 | |
Dec 30 2015 | NEOT | Neothetics, Inc. | Alta Partners VIII, L.P. | Sell | S | 1.44 | 250,000 | 360,000 | 1,339,776 | 1.6 M to 1.3 M (-15.73 %) | |
Dec 30 2015 | NEOT | Neothetics, Inc. | Alta Partners VIII, L.P. | Sell | S | 1.53 | 493,654 | 755,291 | 1,589,776 | 2.1 M to 1.6 M (-23.69 %) | |
Dec 30 2015 | NEOT | Neothetics, Inc. | Alta Partners VIII, L.P. | Sell | S | 1.59 | 54,333 | 86,389 | 2,083,430 | 2.1 M to 2.1 M (-2.54 %) | |
Dec 21 2015 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Sell | S | 1.26 | 598 | 753 | 0 | 598 to 0 (-100.00 %) |
Dec 21 2015 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Sell | S | 1.26 | 1,005 | 1,266 | 0 | 1 K to 0 (-100.00 %) |
Dec 17 2015 | NEOT | Neothetics, Inc. | Alta Partners VIII, L.P. | 10% Owner | Sell | S | 1.44 | 529,261 | 762,136 | 2,137,763 | 2.7 M to 2.1 M (-19.84 %) |
Nov 19 2015 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Option Exercise | M | 1.22 | 2,005 | 2,446 | 11,366 | |
Nov 19 2015 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Option Exercise | M | 1.22 | 4,093 | 4,993 | 23,191 | |
Nov 19 2015 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Sell | S | 8.30 | 6,098 | 50,619 | 293 | 6.4 K to 293 (-95.42 %) |
Nov 19 2015 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Buy | M | 8.30 | 6,098 | 50,619 | 6,391 | 293 to 6.4 K (+2,081.23 %) |
Oct 19 2015 | NEOT | Neothetics, Inc. | Mahaffey George W | President and CEO | Payment of Exercise | F | 8.60 | 26,681 | 229,457 | 171,040 | 197.7 K to 171 K (-13.49 %) |
Sep 25 2015 | NEOT | Neothetics, Inc. | ZEINI HANI M | Director | Option Exercise | A | 12.28 | 10,179 | 124,998 | 10,179 | |
Sep 25 2015 | NEOT | Neothetics, Inc. | Nugent Jeffrey M | Director | Option Exercise | A | 12.28 | 10,179 | 124,998 | 10,179 | |
Sep 22 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Option Exercise | M | 1.34 | 1,000 | 1,342 | 50,182 | |
Sep 22 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Sell | S | 12.20 | 1,000 | 12,195 | 10,848 | 11.8 K to 10.8 K (-8.44 %) |
Sep 22 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Buy | M | 1.34 | 1,000 | 1,342 | 11,848 | 10.8 K to 11.8 K (+9.22 %) |
Sep 03 2015 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Option Exercise | M | 1.22 | 3,000 | 3,660 | 30,718 | |
Sep 03 2015 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Sell | S | 11.33 | 3,000 | 33,990 | 492 | 3.5 K to 492 (-85.91 %) |
Sep 03 2015 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Buy | M | 1.22 | 3,000 | 3,660 | 3,492 | 492 to 3.5 K (+609.76 %) |
Aug 10 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Option Exercise | M | 1.22 | 1,000 | 1,220 | 1,710 | |
Aug 10 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Sell | S | 12.88 | 1,000 | 12,880 | 10,848 | 11.8 K to 10.8 K (-8.44 %) |
Aug 10 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Buy | M | 1.22 | 1,000 | 1,220 | 11,848 | 10.8 K to 11.8 K (+9.22 %) |
Jun 18 2015 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 6.29 | 12,450 | 78,311 | 12,450 | |
Jun 18 2015 | NEOT | Neothetics, Inc. | Kamdar Kim P. | Director | Option Exercise | A | 6.29 | 23,940 | 150,583 | 23,940 | |
Jun 17 2015 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | A | 6.29 | 12,450 | 78,311 | 12,450 | |
Jun 17 2015 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | A | 6.29 | 23,940 | 150,583 | 23,940 | |
Jun 17 2015 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 6.29 | 12,450 | 78,311 | 12,450 | |
Jun 17 2015 | NEOT | Neothetics, Inc. | DEMSKI MARTHA J | Director | Option Exercise | A | 6.29 | 9,722 | 61,151 | 9,722 | |
Jun 17 2015 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Option Exercise | A | 6.29 | 12,450 | 78,311 | 12,450 | |
Jun 17 2015 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Option Exercise | A | 6.29 | 23,940 | 150,583 | 23,940 | |
Jun 16 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Option Exercise | M | 1.22 | 10,848 | 13,235 | 0 | |
Jun 16 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Buy | M | 1.22 | 10,848 | 13,235 | 10,848 | 0 to 10.8 K |
Mar 20 2015 | NEOT | Neothetics, Inc. | Mahaffey George W | President and CEO | Buy | P | 7.76 | 1,000 | 7,757 | 197,721 | 196.7 K to 197.7 K (+0.51 %) |
Feb 12 2015 | NEOT | Neothetics, Inc. | Locke Kenneth W | Chief Scientific Of ... | Option Exercise | A | 6.79 | 16,288 | 110,596 | 16,288 | |
Feb 12 2015 | NEOT | Neothetics, Inc. | KROCHMAL LINCOLN | Chief Medical Offic ... | Option Exercise | A | 6.79 | 16,288 | 110,596 | 16,288 | |
Feb 12 2015 | NEOT | Neothetics, Inc. | Knudson Susan A. | Chief Financial Off ... | Option Exercise | A | 6.79 | 45,607 | 309,672 | 45,607 | |
Feb 12 2015 | NEOT | Neothetics, Inc. | Kemmerer Christopher | VP, Pharma Dev & Ma ... | Option Exercise | A | 6.79 | 42,350 | 287,557 | 42,350 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | M | 8.54 | 2,827 | 24,143 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | M | 8.54 | 1,570 | 13,408 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | C | 0.00 | 102,282 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | C | 0.00 | 36,913 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | C | 0.00 | 104,247 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Option Exercise | C | 0.00 | 12,578 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Payment of Exercise | F | 14.00 | 1,725 | 24,150 | 48,023 | 49.7 K to 48 K (-3.47 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Buy | M | 8.54 | 2,827 | 24,143 | 49,748 | 46.9 K to 49.7 K (+6.03 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Payment of Exercise | F | 14.00 | 958 | 13,412 | 46,921 | 47.9 K to 46.9 K (-2.00 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Buy | M | 8.54 | 1,570 | 13,408 | 47,879 | 46.3 K to 47.9 K (+3.39 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Buy | C | 0.00 | 46,309 | 0 | 46,309 | 0 to 46.3 K |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | M | 8.54 | 165,790 | 1,415,847 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | M | 8.54 | 92,105 | 786,577 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | C | 0.00 | 7,252,144 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | C | 0.00 | 2,164,305 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | C | 0.00 | 6,111,968 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | C | 0.00 | 737,422 | 0 | 0 | |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Buy | P | 14.00 | 70,000 | 980,000 | 3,091,642 | 3 M to 3.1 M (+2.32 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Payment of Exercise | F | 14.00 | 101,132 | 1,415,848 | 3,021,642 | 3.1 M to 3 M (-3.24 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Buy | M | 8.54 | 165,790 | 1,415,847 | 3,122,774 | 3 M to 3.1 M (+5.61 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Payment of Exercise | F | 14.00 | 56,185 | 786,590 | 2,956,984 | 3 M to 3 M (-1.86 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Buy | M | 8.54 | 92,105 | 786,577 | 3,013,169 | 2.9 M to 3 M (+3.15 %) |
Nov 26 2014 | NEOT | Neothetics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Buy | C | 0.00 | 2,921,064 | 0 | 2,921,064 | 0 to 2.9 M |
Nov 25 2014 | NEOT | Neothetics, Inc. | RMI Investments S.a.r.l. | 10% Owner | Option Exercise | C | 0.00 | 9,244,852 | 0 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | RMI Investments S.a.r.l. | 10% Owner | Buy | P | 14.00 | 70,000 | 980,000 | 1,585,549 | 1.5 M to 1.6 M (+4.62 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | RMI Investments S.a.r.l. | 10% Owner | Buy | C | 0.00 | 1,515,549 | 0 | 1,515,549 | 0 to 1.5 M |
Nov 25 2014 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Option Exercise | C | 0.00 | 9,244,852 | 0 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Buy | P | 14.00 | 70,000 | 980,000 | 1,585,549 | 1.5 M to 1.6 M (+4.62 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | Gorbachev Maxim | Director | Buy | C | 0.00 | 1,515,549 | 0 | 1,515,549 | 0 to 1.5 M |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | X | 1.40 | 214,285 | 299,999 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | X | 1.40 | 707,142 | 989,999 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | X | 1.85 | 432,432 | 799,999 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | C | 0.00 | 4,489,065 | 0 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | C | 0.00 | 2,201,220 | 0 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | C | 0.00 | 6,216,215 | 0 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Option Exercise | C | 0.00 | 750,000 | 0 | 0 | |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Buy | P | 14.00 | 70,000 | 980,000 | 2,667,024 | 2.6 M to 2.7 M (+2.70 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Sell | S | 14.00 | 21,429 | 300,006 | 2,597,024 | 2.6 M to 2.6 M (-0.82 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Buy | X | 8.54 | 35,128 | 299,993 | 2,618,453 | 2.6 M to 2.6 M (+1.36 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Sell | S | 14.00 | 70,714 | 989,996 | 2,583,325 | 2.7 M to 2.6 M (-2.66 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Buy | X | 8.54 | 115,925 | 990,000 | 2,654,039 | 2.5 M to 2.7 M (+4.57 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Sell | S | 14.00 | 57,143 | 800,002 | 2,538,114 | 2.6 M to 2.5 M (-2.20 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Buy | X | 11.29 | 93,676 | 1,057,602 | 2,595,257 | 2.5 M to 2.6 M (+3.74 %) |
Nov 25 2014 | NEOT | Neothetics, Inc. | JANNEY DANIEL | Director | Buy | C | 0.00 | 735,912 | 0 | 2,501,581 | 1.8 M to 2.5 M (+41.68 %) |